• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25144 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Swiss Federal Office of Public Health (FOPH) Trikafta® for the treatment of patients with cystic fibrosis: an exploratory economic evaluation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical and instrumental swallowing assessments for dysphagia
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Magnetic resonance neurography in peripheral neuropathy or plexopathy]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (gastric cancer - GC)]
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of antibiotic therapy for neisseria gonorrhoeae infection
2024     NIHR Health Technology Assessment programme Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Intra-articular hyaluronic acid for osteoarthritis of the hip, shoulder, and ankle
2024     NIHR Health Technology Assessment programme Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT
2024     Scottish Health Technologies Group (SHTG) Genotype testing to guide clopidogrel use after an ischaemic stroke or transient ischaemic attack (TIA)
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aerosol therapy with inhalers during mechanical ventilation
2024     National Institute for Health and Care Excellence (NICE) Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension. NICE technology appraisal guidance 1009
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Opioid-sparing effects of IV acetaminophen for patients undergoing surgery
2024     National Institute for Health and Care Excellence (NICE) Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments. NICE technology appraisal guidance 1008
2024     Penn Medicine Center for Evidence-based Practice (CEP) Indications for urinary catheterization in sedated patients
2024     NIHR Health Technology Assessment programme Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
2024     HTA South [Artificial intelligence in breast cancer screening with mammography]
2024     National Institute for Health and Care Excellence (NICE) Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. NICE technology appraisal guidance 1007
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Partially hydrolyzed formula to prevent cow’s milk allergy]
2024     Center for Drug Evaluation (CDE) [HTA for Medical Device: Metallic biliary stents (Rapid HTA report)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, ≥ 2 years, at least one non-class I mutation, excluding F508del and gating mutations) – Benefit assessment according to §35a Social Code Book V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Presumed penicillin allergies: risk assessment for optimal and safe use of betalactams]
2025     National Institute for Health and Care Excellence (NICE) Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment. NICE HealthTech guidance 759
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, ≥ 2 years, at least 1 non-class I mutation, including gating mutation, excluding F508del mutation) – Benefit assessment according to §35a Social Code Book V]
2025     NIHR Health Technology Assessment programme The Knee Arthroplasty versus Joint Distraction Study for Osteoarthritis (KARDS): lessons learnt from an internal pilot trial
2025     National Institute for Health and Care Excellence (NICE) Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment. NICE HealthTech guidance 757
2025     The Danish Health Technology Council (DHTC) [Assessment of endovascular aortic repair (EVAR)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC, first line, combination with lazertinib) - Addendum to Project A25-08]
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of a standardised diagnostic assessment for children and adolescents with emotional difficulties: the STADIA multi-centre RCT
2025     National Institute for Health and Care Excellence (NICE) One-piece closed bags for colostomies: late-stage assessment. NICE HealthTech guidance 754
2025     The Danish Health Technology Council (DHTC) [Assessment of percutaneous vertebroplasty (PVP) for compression fractures]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sarilumab (polymyalgia rheumatica) – Addendum to Project A25-18]
2025     NIHR Health Technology Assessment programme High or low dose oxytocin for nulliparous women delayed in the first stage of labour: the HOLDS RCT
2025     National Institute for Health and Care Excellence (NICE) Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment. NICE HealthTech guidance 753
2025     The Danish Health Technology Council (DHTC) [Assessment of Merlin Assay for diagnosis of malignant melanoma]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipavibart (pre exposure prophylaxis of COVID 19) – Addendum to Project A25-28]
2025     NIHR Health Technology Assessment programme An exploration of the factors influencing successful implementation, delivery and outcomes in an intensive care sedation study: process evaluation of the A2B RCT
2025     National Institute for Health and Care Excellence (NICE) Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment. NICE HealthTech guidance 751
2025     The Danish Health Technology Council (DHTC) [Assessment of supervised gait training]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (complement 3 glomerulopathy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     National Institute for Health and Care Excellence (NICE) Drug-eluting stents for treating coronary artery disease: late-stage assessment. NICE HealthTech guidance 747
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Rheumatoid Arthritis“]
2025     The Danish Health Technology Council (DHTC) [Assessment of SelfBack App for lower back pain]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tiratricol (Allan-Herndon-Dudley syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     National Institute for Health and Care Excellence (NICE) Slide sheets for moving or repositioning a person: late-stage assessment. NICE HealthTech guidance 745
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of colorectal cancer in people with a family risk]
2025     The Danish Health Technology Council (DHTC) [Assessment of HAL-assisted TUR-BT]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Serplulimab (small cell lung cancer, first line) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V]
2025     The Danish Health Technology Council (DHTC) [Assessment of point-of-care tests for use at home for elderly patients]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipavibart (pre exposure prophylaxis of COVID 19) – 2nd Addendum to Project A25-28]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – Belumosudil (chronic graft-versus-host disease)]
2025     The Danish Health Technology Council (DHTC) [Assessment of forearm fractures in children]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Normothermic organ preservation with functional monitoring in liver transplantation - Assessment according to §137h Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efgartigimod alfa (Chronic inflammatory demyelinating polyneuropathy) – Benefit assessment according to § 35a SGB V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for aortic aneurysm interventions]
2025     The Danish Health Technology Council (DHTC) [Assessment of treatment of knee pain]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – 3rd Addendum to Project H23-03]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer, non-advanced) – Benefit assessment according to § 35a SGB V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [In-toto thrombectomy using a retriever/aspiration system for acute pulmonary artery embolism]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (urothelial carcinoma) – Benefit assessment according to § 35a SGB V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Diabetic foot infection in adults: optimal use of antibiotic therapy and measures to prevent recurrence]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V]
2025     National Institute for Health and Care Excellence (NICE) Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease. NICE technology appraisal guidance 1035
2025     NIHR Health Technology Assessment programme OrthoticS for TReatment of symptomatic flat feet In CHildren (OSTRICH): a randomised controlled trial
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odronextamab (DLBCL) – Benefit assessment according to § 35a SGB V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for major liver resection]
2025     National Institute for Health and Care Excellence (NICE) Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal). NICE technology appraisal guidance 1032
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odronextamab (follicular lymphoma) – Benefit assessment according to § 35a SGB V]
2025     National Institute for Health and Care Excellence (NICE) Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours. NICE technology appraisal guidance 1034
2025     NIHR Health Technology Assessment programme Medical management and intervention (using neurosurgical resection or stereotactic radiosurgery) versus medical management alone for symptomatic brain cavernoma: the CARE pilot RCT
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inavolisib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2025     National Institute for Health and Care Excellence (NICE) Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over. NICE technology appraisal guidance 1031
2025     NIHR Health Technology Assessment programme Optimising cardiac surgery outcomes in people with diabetes: the OCTOPuS pilot feasibility study
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (newly diagnosed multiple myeloma, eligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V]
2025     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal). NICE technology appraisal guidance 1028
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of percutaneous nephrolithotomy, flexible ureterorenoscopy and extracorporeal shockwave lithotripsy for lower pole stones: the PUrE RCTs
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2025     National Institute for Health and Care Excellence (NICE) Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal). NICE technology appraisal guidance 1029
2025     NIHR Health Technology Assessment programme Glycaemic control in labour with diabetes: GILD, a scoping study
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V]
2025     National Institute for Health and Care Excellence (NICE) Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1030
2025     NIHR Health Technology Assessment programme Determining optimal strategies for primary prevention of cardiovascular disease: a synopsis of an evidence synthesis study
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2025     National Institute for Health and Care Excellence (NICE) Tebentafusp for treating advanced uveal melanoma. NICE technology appraisal guidance 1027
2025     Austrian Institute for Health Technology Assessment (AIHTA) Islet cell transplantation for chronic pancreatitis, type 1 diabetes, with and without kidney transplantation
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for belumosudil (chronic graft-versus-host disease) – First addendum to Project A25-34]
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of extending population-based breast cancer screening to women aged 45–49 and 70–74 and the use of digital breast tomosynthesis in screening women with dense breast tissue]
2025     National Institute for Health and Care Excellence (NICE) Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults. NICE interventional procedures guidance 799
2025     Austrian Institute for Health Technology Assessment (AIHTA) Drug-coated balloon catheter for the treatment of urethral strictures
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (giant cell arteritis) – Addendum to Project A25-66]
2025     WorkSafeBC External trigeminal nerve stimulation (e-TNS) in treating and preventing migraine headaches
2025     National Institute for Health and Care Excellence (NICE) Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE interventional procedures guidance 798
2025     Austrian Institute for Health Technology Assessment (AIHTA) Thermal ablation for early-stage breast cancer: cryoablation, microwave, radiofrequency, high-intensity focused ultrasound, and laser ablation
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Addendum to Project A25-67]
2025     WorkSafeBC Platelet rich plasma (PRP) in treating post-fracture ankle pain
2025     NIHR Health Technology Assessment programme Development of a clinical decision support tool for Primary care Management of lower Urinary tract Symptoms in men: the PriMUS study
2025     Austrian Institute for Health Technology Assessment (AIHTA) One-stage matrix-assisted cartilage repair with and without bone marrow aspirate concentrate in the knee
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Deutivacaftor/tezacaftor/vanzacaftor (cystic fibrosis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]